U.S. Markets closed
  • S&P Futures

    4,117.25
    -9.25 (-0.22%)
     
  • Dow Futures

    33,663.00
    -40.00 (-0.12%)
     
  • Nasdaq Futures

    13,726.25
    -68.00 (-0.49%)
     
  • Russell 2000 Futures

    2,180.80
    -3.20 (-0.15%)
     
  • Crude Oil

    62.61
    +0.17 (+0.27%)
     
  • Gold

    1,782.90
    +4.50 (+0.25%)
     
  • Silver

    25.93
    +0.09 (+0.35%)
     
  • EUR/USD

    1.2035
    -0.0006 (-0.0481%)
     
  • 10-Yr Bond

    1.5620
    -0.0390 (-2.44%)
     
  • Vix

    18.68
    +1.39 (+8.04%)
     
  • GBP/USD

    1.3933
    -0.0004 (-0.0265%)
     
  • USD/JPY

    107.9560
    -0.1140 (-0.1055%)
     
  • BTC-USD

    56,094.20
    +1,297.21 (+2.37%)
     
  • CMC Crypto 200

    1,285.42
    +51.01 (+4.13%)
     
  • FTSE 100

    6,859.87
    -140.21 (-2.00%)
     
  • Nikkei 225

    28,462.20
    -638.18 (-2.19%)
     

Newscope Announces DTC Eligibility of Its Common Shares in the United States

  • Oops!
    Something went wrong.
    Please try again later.
Newscope Capital Corporation
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

TORONTO, March 01, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (the “Company” or “Newscope”) (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce today that its common shares are now eligible for electronic clearing and settlement through The Depository Trust Company ("DTC") in the United States. In addition to trading in the United States on the OTCQB Venture Market under the symbol “PHRRF”, the Company’s common shares continue to trade on the Canadian Securities Exchange under “PHRM”.

“Following our recent listing on the OTCQB Venture Market, we are pleased to have received DTC eligibility, as it is expected to increase accessibility and visibility of our common shares for U.S investors, and increase liquidity and broaden our shareholder base in the U.S.,” said Fabio Chianelli, CEO of the Company. “We are positioned to communicate our passion in developing novel uses and formulations of ketamine and the delivery via a microneedle patch of psychedelics such as ketamine, psilocybin, MDMA, DMT and LSD for neuropsychiatric, neurological and neuromuscular diseases.”

DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies. Securities that are eligible to be electronically cleared and settled through DTC are considered “DTC eligible”. DTC services reduces costs and accelerates the settlement process for investors and brokers trading Canadian securities in the United States.

About Newscope Capital Corporation

Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc., is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals for FDA approval to treat neuropsychiatric, neurological and neuromuscular diseases.

Learn more at: PharmaTher.com and follow us on Twitter and LinkedIn.

For more information, please contact:

Fabio Chianelli
Chief Executive Officer
Newscope Capital Corporation (d/b/a PharmaTher Inc.)
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “potential”, “aim” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Newscope Capital Corporation’s (the “Company”) current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the period of November 30, 2020 (“MD&A”), dated January 27, 2021, which is available on the Company’s profile at www.sedar.com.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.